Will Zimmer Biomet Holdings Inc Go Down Anytime Soon? Option Trader Doubt That

 Will Zimmer Biomet Holdings Inc Go Down Anytime Soon? Option Trader Doubt That

In today’s session Zimmer Biomet Holdings Inc (ZBH) registered an unusually high (863) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious ZBH increase. With 863 contracts traded and 1154 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: ZBH161118C00140000 closed last at: $0.85 or 0% . About 203,958 shares traded hands. Zimmer Biomet Holdings Inc (NYSE:ZBH) has risen 26.14% since March 9, 2016 and is uptrending. It has outperformed by 18.73% the S&P500.

Analysts await Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings on November, 3. They expect $1.79 EPS, up 9.15% or $0.15 from last year’s $1.64 per share. ZBH’s profit will be $341.48M for 17.67 P/E if the $1.79 EPS becomes a reality. After $2.02 actual EPS reported by Zimmer Biomet Holdings Inc for the previous quarter, Wall Street now forecasts -11.39% negative EPS growth.

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Out of 15 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 12 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 80% are positive. $155 is the highest target while $105 is the lowest. The $130.57 average target is 3.18% above today’s ($126.54) stock price. Zimmer Biomet Holdings has been the topic of 22 analyst reports since August 27, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Needham given on Friday, July 29. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) earned “Buy” rating by Sterne Agee CRT on Wednesday, November 4. The stock has “Buy” rating given by Zacks on Friday, August 28. SunTrust initiated it with “Buy” rating and $155 target price in Thursday, August 11 report. The stock has “Outperform” rating given by RBC Capital Markets on Monday, November 2. UBS initiated the shares of ZBH in a report on Tuesday, September 22 with “Neutral” rating. The rating was maintained by Barclays Capital with “Overweight” on Tuesday, August 23. The firm earned “Buy” rating on Friday, September 4 by Canaccord Genuity. Nomura initiated it with “Buy” rating and $123 target price in Thursday, March 17 report. The firm has “Outperform” rating given on Friday, October 9 by Credit Suisse.

According to Zacks Investment Research, “Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.”

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company has a market cap of $24.14 billion. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It has a 113.78 P/E ratio. The Firm manages its activities through three geographic operating divisions: the Americas, consists of the United States and includes other North, Central and South American markets; EMEA, consists of Europe and includes the Middle East and African markets, and Asia Pacific, consists of Japan and includes other Asian and Pacific markets.

ZBH Company Profile

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., incorporated on January 12, 2001, is engaged in designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma (S.E.T.) products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Firm manages its activities through three geographic operating divisions: the Americas, comprising principally of the United States and includes other North, Central and South American markets; EMEA, comprising of principally of Europe and includes the Middle East and African markets, and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company’s four product category divisions include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic (CMF) and Dental.

More recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Forbes.com which released: “Ex-Dividend Reminder: Piedmont Natural Gas, Zimmer Biomet Holdings and Pembina …” on September 19, 2016. Also Prnewswire.com published the news titled: “Zimmer Biomet Completes Tender Offer for Outstanding Shares of LDR Holding …” on July 13, 2016. Prnewswire.com‘s news article titled: “Zimmer Biomet Contributes Additional $100000 in Funding to the Orthopaedic …” with publication date: September 22, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment